- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00392743
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
November 1, 2012 updated by: GlaxoSmithKline
An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained with SB773812, and to accurately interpret future D2 RO results from either PET or SPECT studies with new compounds.
Study Overview
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08025
- GSK Investigational Site
-
Barcelona, Spain, 08036
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Barcelona, Spain, 08003
- GSK Investigational Site
-
Barcelona, Spain
- GSK Investigational Site
-
Espluges de Llobregat, Spain, 08950
- GSK Investigational Site
-
Sant Boi de Llobregat, Spain, 08830
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This is a methodology study.
Description
Inclusion criteria:
- Not pregnant or becoming pregnant during the study.
- No abnormality in clinical examination, clinical laboratory test or ECG.
- Not taking drugs
- Patients with schizophrenia, schizophreniform disorder or schizoaffective disorders.
- Patients with at least 1 month antipsychotic monotherapy with either risperidone, olanzapine or clozapine.
- Healthy volunteers with no neurological or psychiatric illness.
Exclusion criteria:
- Have received other antipsychotic during the last month or neuroleptics during the last year.
- If you have taken part in investigations you should not receive a radiation dose of more than 10 mSv over any 3 year period.
- History of bleeding disorder or are taking medication that affects blood clotting
- History of substance dependence (except nicotine)
- Claustrophobia
- Gross head deformity.
- Unable to lie still in the PET or SPECT camera for 1 hour and a half.
- The presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
pet/spect scan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PET and SPECT striatal binding potential
Time Frame: at day 1
|
at day 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
plasma concentrations at the time of scanning,
Time Frame: at day 1
|
at day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
October 24, 2006
First Submitted That Met QC Criteria
October 24, 2006
First Posted (Estimate)
October 26, 2006
Study Record Updates
Last Update Posted (Estimate)
November 4, 2012
Last Update Submitted That Met QC Criteria
November 1, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMT108154
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
Clinical Trials on pet/spect scan
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States
-
Institute for Neurodegenerative DisordersTerminatedAlzheimer DiseaseUnited States
-
UNC Lineberger Comprehensive Cancer CenterTerminatedThoracic | Pulmonary Injury | Heart InjuriesUnited States
-
Lille Catholic UniversityRecruitingHeart Diseases | Brain Diseases | Kidney Diseases | Thyroid Diseases | Bone DiseasesFrance
-
UNC Lineberger Comprehensive Cancer CenterCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Completed
-
University of ExeterRecruitingParkinson's Disease | Parkinson Disease | Neurodegenerative Diseases | Positron Emission Tomography | Neurodegeneration | Parkinson'sUnited Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Stanford UniversityCompletedPrimary Malignant Liver NeoplasmUnited States